Evolus, Inc.

NASDAQ:EOLS

Drug Manufacturers - Specialty & Generic

Healthcare
$7.07 -2.00%

-$0.14 today

Market cap
$467.95M
Beta
1.33
P/E (TTM)
-9.9
EPS (TTM)
-$0.67
52W Low $3.86High $10.20

Volume 0.80M

Average 0.86M

EOLS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Evolus, Inc.NASDAQ: EOLS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $5.12M fell 13.7% year over year, in line with the -13.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 0.6% from the prior quarter. Over 3 fiscal years it compounded at +24.1% a year.

Context

  • Stock-based compensation amounted to 7.0% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -13.7% holds above the trailing-twelve-month pace of -13.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.12M-0.6% QoQ
Last fiscal yearDec 2025
$20.7M-7.0% YoY
LTMMar 2026
$19.89M-13.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.7%——
1 year-7.0%——
3-year CAGR+24.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
20.7M USD
Year-over-year change
-7.0%
4-year CAGR
+21.3%

Stock-Based Compensation vs competitors

How EOLS compares with its peers on the latest reported figures

No competitor Stock-Based Compensation figures are available to compare.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(46.81M)(74.41M)(61.69M)(50.42M)(51.64M)
Depreciation & Amortization6.31M4.5M5.87M6.02M8.74M
Deferred Income Tax15K(18K)5K(21K)21K
Stock-Based Compensation9.58M10.83M16.46M22.25M20.7M
Change in Working Capital(11.54M)(34.25M)(5.9M)(6.6M)(22.48M)
Accounts Receivables(5.57M)(9.39M)(9.52M)(19.6M)(11.51M)
Inventory(2.98M)(10.69M)4.19M3.25M(11.12M)
Accounts Payables(787K)968K(1.02M)391K10.1M
Other Working Capital(2.21M)(15.14M)450K9.36M(9.95M)
Other Non-Cash Items9.06M8.44M11.24M10.77M2.39M
Operating Cash Flow(33.39M)(84.91M)(34.01M)(18M)(42.27M)
Capital Expenditures(970K)(2.94M)(1.63M)(1.47M)(3.44M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments5M0000
Other Investing Activities(577K)(1.32M)(1.15M)(3.35M)0
Investing Cash Flow4.03M(2.94M)(1.63M)(4.82M)(8.45M)
Debt Repayment(24.37M)050M0(15K)
Common Stock Issued103.34M0051.21M1.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(5.92M)(4.15M)(5.36M)(3.8M)16.19M
Financing Cash Flow73.05M(4.15M)44.64M47.41M17.34M
Effect of Forex Changes(1)(337K)(90K)(478K)254K
Net Change in Cash43.69M(92.33M)8.92M24.11M(33.13M)
Free Cash Flow(34.36M)(87.85M)(35.64M)(19.47M)(45.71M)

Evolus, Inc.

NASDAQ:EOLS

Intrinsic Alpha fair value

Locked

Current Price

$7.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.